ECSP14020402A - Polipéptidos de unión a cx3cr1 - Google Patents

Polipéptidos de unión a cx3cr1

Info

Publication number
ECSP14020402A
ECSP14020402A ECIEPI201420402A ECPI201420402A ECSP14020402A EC SP14020402 A ECSP14020402 A EC SP14020402A EC IEPI201420402 A ECIEPI201420402 A EC IEPI201420402A EC PI201420402 A ECPI201420402 A EC PI201420402A EC SP14020402 A ECSP14020402 A EC SP14020402A
Authority
EC
Ecuador
Prior art keywords
polypeptides
cx3cr1
binding polypeptides
compositions
relates
Prior art date
Application number
ECIEPI201420402A
Other languages
English (en)
Spanish (es)
Inventor
Hoorick Diane Van
Sanjaya Singh
Cedric Jozef Néotère Ververken
Erik Depla
Toon Laeremans
Alisa K Waterman
Original Assignee
Sanofi Aventis Deutschiand Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14020402(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschiand Gmbh filed Critical Sanofi Aventis Deutschiand Gmbh
Publication of ECSP14020402A publication Critical patent/ECSP14020402A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
ECIEPI201420402A 2012-02-27 2014-09-25 Polipéptidos de unión a cx3cr1 ECSP14020402A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261603622P 2012-02-27 2012-02-27

Publications (1)

Publication Number Publication Date
ECSP14020402A true ECSP14020402A (es) 2015-11-30

Family

ID=47884535

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201420402A ECSP14020402A (es) 2012-02-27 2014-09-25 Polipéptidos de unión a cx3cr1

Country Status (27)

Country Link
US (6) US9035029B2 (en:Method)
EP (2) EP4050027A3 (en:Method)
JP (1) JP6101715B2 (en:Method)
KR (1) KR102008136B1 (en:Method)
CN (3) CN104245735B (en:Method)
AP (1) AP2014007791A0 (en:Method)
AR (1) AR090158A1 (en:Method)
AU (1) AU2013226340B2 (en:Method)
CA (1) CA2862182A1 (en:Method)
CL (1) CL2014002072A1 (en:Method)
EA (1) EA028183B1 (en:Method)
EC (1) ECSP14020402A (en:Method)
GE (1) GEP201706773B (en:Method)
IL (3) IL291571B2 (en:Method)
IN (1) IN2014DN05756A (en:Method)
MD (1) MD4548C1 (en:Method)
MX (1) MX349192B (en:Method)
NZ (1) NZ627260A (en:Method)
PE (1) PE20141859A1 (en:Method)
PH (2) PH12021553014A1 (en:Method)
SG (1) SG11201405283SA (en:Method)
TN (1) TN2014000360A1 (en:Method)
TW (1) TWI598361B (en:Method)
UA (1) UA115781C2 (en:Method)
UY (1) UY34644A (en:Method)
WO (1) WO2013130381A1 (en:Method)
ZA (3) ZA201405021B (en:Method)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
AP2014007791A0 (en) 2012-02-27 2014-07-31 Boehringer Ingelheim Int CX3CR1-binding polypeptides
WO2015026884A1 (en) * 2013-08-21 2015-02-26 Boehringer Ingelheim International Gmbh Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MX2018000948A (es) 2015-07-23 2018-09-27 Inhibrx Inc Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
RU2022106508A (ru) 2016-01-11 2022-04-05 Инхибркс, Инк. Поливалентные и полиспецифические ох40-связывающие слитые белки
CN109071667A (zh) * 2016-03-08 2018-12-21 马弗里克治疗公司 可诱导性结合蛋白和使用方法
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
JP7112735B2 (ja) * 2016-11-29 2022-08-04 国立研究開発法人国立精神・神経医療研究センター 進行型免疫性脱髄疾患の予防、発症抑制又は治療剤
US20190367623A1 (en) * 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
IL317013A (en) 2017-09-08 2025-01-01 Takeda Pharmaceuticals Co Binding proteins are activated under limited conditions
SG11202101173TA (en) 2018-08-13 2021-03-30 Inhibrx Inc Ox40-binding polypeptides and uses thereof
EP3934762A1 (en) 2019-03-05 2022-01-12 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN110675421B (zh) * 2019-08-30 2022-03-15 电子科技大学 基于少量标注框的深度图像协同分割方法
WO2022165434A2 (en) * 2021-02-01 2022-08-04 The General Hospital Corporation Fc-enhanced antibodies for prevention and treatment of ebola virus infection
TW202246334A (zh) * 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
KR20250040019A (ko) 2022-07-18 2025-03-21 아블린쓰 Cx3cr1 결합 화합물, 이의 용도, 및 관련 방법
AU2023410319A1 (en) 2022-12-22 2025-05-29 Chiome Bioscience Inc. Anti-human cx3cr1 antibody
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452207T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
WO2001060406A1 (en) * 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US6905688B2 (en) 2000-04-12 2005-06-14 Human Genome Sciences, Inc. Albumin fusion proteins
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
JP4123856B2 (ja) 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP1511850A4 (en) 2002-06-10 2006-06-07 Metabolex Inc METHODS OF TREATING AND DIAGNOSING DIABETES USING MODULATORS OF CX3CR1
EP2267027A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP2221317A3 (en) 2003-06-30 2011-07-27 Domantis Limited PEGylated single domain antibodies (dAb)
WO2005103684A2 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
WO2006046739A1 (ja) 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 炎症性疾患治療剤
PT2949668T (pt) 2005-05-18 2019-10-24 Ablynx Nv Nanobodies tm melhorados contra fator-alfa de necrose tumoral.
EP1945257A4 (en) 2005-08-08 2009-05-06 Onconon Llc ANTIBODY COMPOSITIONS, METHODS OF TREATING NEOPLASTIC DISEASE, AND METHOD FOR REGULATING FERTILITY
JP5364870B2 (ja) * 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2069402A2 (en) * 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
CN101611056A (zh) 2006-12-05 2009-12-23 埃博灵克斯股份有限公司 能够结合于血清蛋白的肽
WO2009109635A2 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
US8217140B2 (en) 2008-04-17 2012-07-10 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2010070394A1 (en) 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
EP2486056A1 (en) * 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011044377A2 (en) 2009-10-09 2011-04-14 Cell Point, Llc Chelator-targeting ligand conjugates for cardiovascular imaging
EP2648754A4 (en) * 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
AP2014007791A0 (en) 2012-02-27 2014-07-31 Boehringer Ingelheim Int CX3CR1-binding polypeptides
WO2015026884A1 (en) 2013-08-21 2015-02-26 Boehringer Ingelheim International Gmbh Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease

Also Published As

Publication number Publication date
MX349192B (es) 2017-07-18
AR090158A1 (es) 2014-10-22
EP4050027A3 (en) 2022-11-30
IN2014DN05756A (en:Method) 2015-04-10
WO2013130381A1 (en) 2013-09-06
TW201348256A (zh) 2013-12-01
PE20141859A1 (es) 2014-12-17
UA115781C2 (uk) 2017-12-26
CA2862182A1 (en) 2013-09-06
IL291571B2 (en) 2024-08-01
US9783612B2 (en) 2017-10-10
SG11201405283SA (en) 2014-10-30
IL291571B1 (en) 2024-04-01
EP2820046B1 (en) 2022-06-15
HK1205154A1 (en) 2015-12-11
IL234018A0 (en) 2014-09-30
ZA201405021B (en) 2024-09-25
US20180030141A1 (en) 2018-02-01
CL2014002072A1 (es) 2015-01-23
AU2013226340B2 (en) 2017-06-22
US20130224224A1 (en) 2013-08-29
IL234018B2 (en) 2023-05-01
IL291571A (en) 2022-05-01
CN115925938A (zh) 2023-04-07
US20230046772A1 (en) 2023-02-16
ZA202308845B (en) 2025-03-26
AP2014007791A0 (en) 2014-07-31
EA028183B1 (ru) 2017-10-31
US9035029B2 (en) 2015-05-19
KR102008136B1 (ko) 2019-08-08
PH12014501912A1 (en) 2014-11-24
US11384151B2 (en) 2022-07-12
NZ627260A (en) 2015-10-30
CN108610421B (zh) 2022-08-19
CN104245735B (zh) 2018-02-23
US12221487B2 (en) 2025-02-11
AU2013226340A1 (en) 2014-07-31
US20240279349A2 (en) 2024-08-22
CN104245735A (zh) 2014-12-24
UY34644A (es) 2013-09-02
US20160355595A1 (en) 2016-12-08
EA201400964A1 (ru) 2015-02-27
IL234018B1 (en) 2023-01-01
ZA202308846B (en) 2025-03-26
US10385134B2 (en) 2019-08-20
US20240026013A2 (en) 2024-01-25
JP6101715B2 (ja) 2017-03-22
US20150239971A1 (en) 2015-08-27
EP4050027A2 (en) 2022-08-31
GEP201706773B (en) 2017-11-27
MD20140104A2 (ro) 2015-02-28
IL311502A (en) 2024-05-01
PH12014501912B1 (en) 2023-01-18
PH12021553014A1 (en) 2022-09-05
US20190322753A1 (en) 2019-10-24
US9458235B2 (en) 2016-10-04
BR112014021080A2 (pt) 2017-07-04
CN108610421A (zh) 2018-10-02
MD4548C1 (ro) 2018-08-31
MD4548B1 (ro) 2018-01-31
TWI598361B (zh) 2017-09-11
EP2820046A1 (en) 2015-01-07
TN2014000360A1 (en) 2015-12-21
MX2014009864A (es) 2014-10-24
KR20140130685A (ko) 2014-11-11
JP2015509368A (ja) 2015-03-30

Similar Documents

Publication Publication Date Title
ECSP14020402A (es) Polipéptidos de unión a cx3cr1
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
EA201492101A1 (ru) Антитела против fcrn
UY33588A (es) Moleculas de union a vegf
CR20170079A (es) Agentes de unión a cd123 y usos de estos
PE20151146A1 (es) Proteinas de union al antigeno bcma
PH12015501651A1 (en) Antibody constructs for cdh19 and cd3
CO7250445A2 (es) Proteínas de unión a antígeno st2
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
MX374682B (es) Moléculas de unión a 4-1bb.
PH12016500275A1 (en) Antibodies
ECSP18046820A (es) Polipéptidos que inhiben cd40l
PH12015501687A1 (en) Novel binding proteins from pcsk9
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.